Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 6:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,699 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Clinical Trial Matching Clear all
Completed Phase 3 Interventional Results available

Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED)

NCT04845620
View directory record Official record
Conditions
Atopic Dermatitis Eczema
Interventions
Roflumilast Cream 0.05%, Vehicle Cream
Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
2 Years to 5 Years
Enrollment
652 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
71
States / cities
Birmingham, Alabama • Montgomery, Alabama • Gilbert, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Sep 1, 2026, 6:03 PM EDT
Completed Phase 2 Interventional

A Clinical Trial of STP0404 in Adults With HIV-1 Infection

NCT05869643
View directory record Official record
Conditions
HIV-1-infection
Interventions
Low-dose STP0404 (Pirmitegravir), Medium-dose STP0404 (Pirmitegravir), High-dose STP0404 (Pirmitegravir), Placebo
Drug
Lead sponsor
ST Pharm Co., Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
13
States / cities
Los Angeles, California • Ft. Pierce, Florida • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 1, 2026, 6:03 PM EDT
Completed Phase 2 Interventional Results available

Milk Patch for Eosinophilic Esophagitis

NCT02579876
View directory record Official record
Conditions
Eosinophilic Esophagitis, Milk Allergy
Interventions
Viaskin Milk 500 mcg, Viaskin Placebo
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
4 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Sep 1, 2026, 6:03 PM EDT
Completed Phase 3 Interventional Results available

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker

NCT01137474
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Dapagliflozin, Placebo-matching dapagliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 89 Years
Enrollment
2,996 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
164
States / cities
Birmingham, Alabama • Mobile, Alabama • Ozark, Alabama + 124 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2017 · Synced Sep 1, 2026, 6:03 PM EDT
Active, not recruiting Phase 2 Interventional

De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis

NCT05622318
View directory record Official record
Conditions
Graft-versus-host Disease
Interventions
Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil, Ruxolitinib
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
60 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Sep 1, 2026, 6:03 PM EDT
Completed Not applicable Interventional

Improving Faculty's Ability to Speak Up to Others in the Operating Room

NCT02170818
View directory record Official record
Conditions
Faculty, Medical
Interventions
Educational Workshop on Speaking-Up, Unrelated Education (CPR)
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
Not listed
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 22, 2014 · Synced Sep 1, 2026, 6:03 PM EDT
Active, not recruiting No phase listed Observational

Neuroblastoma Precision Trial

NCT02868268
View directory record Official record
Conditions
Neuroblastoma
Interventions
Gene panel sequencing of tumor specimens
Other
Lead sponsor
New Approaches to Neuroblastoma Therapy Consortium
Other
Eligibility
1 Year to 30 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Sep 1, 2026, 6:03 PM EDT
Completed Phase 1 Interventional

An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment

NCT03335540
View directory record Official record
Conditions
Advanced Cancer
Interventions
Nivolumab, Relatlimab, Cabiralizumab, Ipilimumab, IDO1 Inhibitor, Radiation Therapy
Biological · Drug · Radiation
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
4
States / cities
Chicago, Illinois • Baltimore, Maryland • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 25, 2022 · Synced Sep 1, 2026, 6:03 PM EDT
Not listed Not applicable Interventional

Get Going: Accelerometer-Based Intervention to Promote Physical Activity in Frail Older Adults

NCT02635477
View directory record Official record
Conditions
Coronary Artery Disease, Heart Failure
Interventions
Intervention, Control
Behavioral
Lead sponsor
American College of Cardiology
Other
Eligibility
70 Years to 100 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
14
States / cities
Atlanta, Georgia • Boston, Massachusetts • Ann Arbor, Michigan + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2017 · Synced Sep 1, 2026, 6:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Sex-Divergent Effects of Magnesium L-Threonate Supplementation on Sleep Quality, Cognitive Performance, and Neuromuscular Function in Healthy Adults

NCT07706283
View directory record Official record
Conditions
Healthy Adults; Cognitive Performance; Sleep Quality; Neuromuscular Function
Interventions
Magnesium L-threonate, Placebo
Dietary Supplement
Lead sponsor
Barry University
Other
Eligibility
18 Years to 45 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Miami Shores, Florida
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Sep 1, 2026, 6:03 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Neural Mechanisms of Cost and Benefit Integration During Decision-Making, Aim 2: Acute & Lifetime Stress

NCT04060966
View directory record Official record
Conditions
Healthy
Interventions
Cold-Pressor Task (CPT), Control CPT, fMRI
Behavioral · Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 64 Years
Enrollment
397 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Sep 1, 2026, 6:03 PM EDT
Active, not recruiting Not applicable Interventional

RESTORE Declined Livers Study

NCT04483102
View directory record Official record
Conditions
Liver Diseases, Surgery, Transplant; Failure, Liver
Interventions
Declined liver in Normothermic Machine Perfusion (NMP), Standard cold preservation of liver
Device · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Sep 1, 2026, 6:03 PM EDT
Completed Phase 2 Interventional Results available

Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB Patients

NCT02654483
View directory record Official record
Conditions
Epidermolysis Bullosa, Pruritus
Interventions
VPD-737, Placebo
Drug · Other
Lead sponsor
Jean Yuh Tang
Other
Eligibility
13 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 22, 2020 · Synced Sep 1, 2026, 6:03 PM EDT
Not yet recruiting Phase 1 Interventional

²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma

NCT04579523
View directory record Official record
Conditions
Multiple Myeloma, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10, Cyclophosphamide, Fludarabine Phosphate, Total-Body Irradiation, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, X-Ray Imaging
Procedure · Biological · Drug + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 1, 2026, 6:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Pragmatic Trial of An Adaptive eHealth HIV Prevention Program for Diverse Adolescent MSM

NCT03511131
View directory record Official record
Conditions
Hiv, Adolescent Behavior, Sex, Safe
Interventions
Queer Sex Ed, Keep It Up, Keep It Up-Control, Young Men's Health Project
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
13 Years to 18 Years · Male only
Enrollment
1,306 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 11, 2022 · Synced Sep 1, 2026, 6:03 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)

NCT00790400
View directory record Official record
Conditions
Tuberous Sclerosis Complex (TSC), Lymphangioleiomyomatosis (LAM)
Interventions
Everolimus (RAD001), Everolimus Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
6
States / cities
Birmingham, Alabama • Phoenix, Arizona • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2017 · Synced Sep 1, 2026, 6:03 PM EDT
Completed Phase 3 Interventional

"SALT Trial" Study of Ascending Levels of Tolvaptan in Hyponatremia

NCT00072683
View directory record Official record
Conditions
Hyponatremias, Water Intoxication, Inappropriate ADH Syndrome, Water-Electrolyte Imbalances
Interventions
tolvaptan, placebo matching tolvaptan
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
23
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 1, 2026, 6:03 PM EDT
Active, not recruiting Not applicable Interventional

Transcranial Direct Current Stimulation of the Temporal Cortex in Survivors of Childhood Acute Lymphoblastic Leukemia (ALL)

NCT04105530
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Transcranial Direct Current Stimulation, Executive Dysfunction
Interventions
Anodal tDCS treatment, Cathodal tDCS treatment, Sham treatment, NIH Toolbox List Sorting Working Memory Test, NIH Toolbox Flanker Inhibitory Control and Attention Test, Grooved Peg Board Test, Buschke Selective Reminding Test
Device · Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
8 Years to 215 Months
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 11, 2024 · Synced Sep 1, 2026, 6:03 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)

NCT06335173
View directory record Official record
Conditions
Alzheimer Disease
Interventions
sabirnetug, Placebo
Drug
Lead sponsor
Acumen Pharmaceuticals
Industry
Eligibility
50 Years to 90 Years
Enrollment
542 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
44
States / cities
Carlsbad, California • Fullerton, California • Irvine, California + 40 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2025 · Synced Sep 1, 2026, 6:03 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy in Adult Subjects With Acute Migraines

NCT03237845
View directory record Official record
Conditions
Migraine, With or Without Aura
Interventions
Rimegepant, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
50
States / cities
Mobile, Alabama • Glendale, Arizona • Rogers, Arkansas + 44 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Sep 1, 2026, 6:03 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis

NCT06718101
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Lutikizumab, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
19
States / cities
Fountain Hills, Arizona • Los Angeles, California • Sacramento, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 1, 2026, 6:03 PM EDT
Completed Phase 2 Interventional Results available

Preventing Epilepsy Using Vigabatrin In Infants With Tuberous Sclerosis Complex

NCT02849457
View directory record Official record
Conditions
Tuberous Sclerosis Complex
Interventions
Early Vigabatrin, Delayed Vigabatrin (Placebo)
Drug
Lead sponsor
Martina Bebin
Other
Eligibility
1 Day to 6 Months
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
13
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2024 · Synced Sep 1, 2026, 6:03 PM EDT
Recruiting Phase 2 Interventional

Janus Kinase Inhibition to Prevent Ventilator-induced Diaphragm Dysfunction

NCT03681275
View directory record Official record
Conditions
Diaphragm Injury
Interventions
Tofacitinib 10 MG [Xeljanz], Placebo to match Tofacitinib
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 24, 2024 · Synced Sep 1, 2026, 6:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Interventions for Communication in Autism Network

NCT01018407
View directory record Official record
Conditions
Autism
Interventions
Discrete Trial Training, Interpersonal Developmental Approach
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
33 Months to 54 Months
Enrollment
192 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
3
States / cities
Los Angeles, California • Baltimore, Maryland • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 13, 2024 · Synced Sep 1, 2026, 6:03 PM EDT